Grembi Jessica A, Mayer-Blackwell Koshlan, Luby Stephen P, Spormann Alfred M
Department of Civil and Environmental Engineering, Stanford University, Stanford, CA, United States.
Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, United States.
Front Cell Infect Microbiol. 2020 Jul 15;10:351. doi: 10.3389/fcimb.2020.00351. eCollection 2020.
Quantitative molecular diagnostic methods can effectively detect pathogen-specific nucleic acid sequences, but costs associated with multi-pathogen panels hinder their widespread use in research trials. Nano-liter qPCR (nL-qPCR) is a miniaturized tool for quantification of multiple targets in large numbers of samples based on assay parallelization on a single chip, with potentially significant cost-savings due to rapid throughput and reduced reagent volumes. We evaluated a suite of novel and published assays to detect 17 enteric pathogens using a commercially available nL-qPCR technology. Amplification efficiencies ranged from 88 to 98% (mean 91%) and were reproducible across four operators at two separate facilities. When applied to fecal material, assays were sensitive and selective (99.8% of DNA amplified were genes from the target organism). Due to nanofluidic volumes, detection limits were 1-2 orders of magnitude less sensitive for nL-qPCR than an enteric TaqMan Array Card (TAC). However, higher detection limits do not hinder detection of diarrhea-causing pathogen concentrations. Compared to TAC, nL-qPCR displayed 99% (95% CI 0.98, 0.99) negative percent agreement and 62% (95% CI 0.59, 0.65) overall positive percent agreement for presence of pathogens across diarrheal and non-diarrheal fecal samples. Positive percent agreement was 89% among samples with concentrations above the nL-qPCR detection limits. nL-qPCR assays showed an underestimation bias of 0.34 log copies/gram of stool [IQR -0.40, -0.28] compared with TAC. With 12 times higher throughput for a sixth of the per-sample cost of the enteric TAC, the nL-qPCR chip is a viable alternative for enteropathogen quantification for studies where other technologies are cost-prohibitive.
定量分子诊断方法可以有效检测病原体特异性核酸序列,但多病原体检测板相关的成本阻碍了它们在研究试验中的广泛应用。纳升级定量聚合酶链反应(nL-qPCR)是一种基于在单个芯片上进行检测并行化来对大量样本中的多个靶标进行定量的小型化工具,由于通量高和试剂用量减少,可能会显著节省成本。我们使用市售的nL-qPCR技术评估了一套新颖的和已发表的检测17种肠道病原体的方法。扩增效率范围为88%至98%(平均91%),并且在两个不同设施的四名操作人员中具有可重复性。当应用于粪便样本时,检测方法具有敏感性和选择性(99.8%的扩增DNA是来自目标生物体的基因)。由于纳流体体积,nL-qPCR的检测限比肠道TaqMan阵列卡(TAC)低1-2个数量级。然而,较高的检测限并不妨碍对引起腹泻的病原体浓度的检测。与TAC相比,nL-qPCR在腹泻和非腹泻粪便样本中病原体存在情况的阴性百分一致性为99%(95%置信区间0.98, 0.99),总体阳性百分一致性为62%(95%置信区间0.59, 0.65)。在浓度高于nL-qPCR检测限的样本中,阳性百分一致性为89%。与TAC相比,nL-qPCR检测显示每克粪便低估偏差为0.34个对数拷贝[四分位距-0.40, -0.28]。nL-qPCR芯片的通量比肠道TAC高12倍,每个样本的成本仅为其六分之一,对于其他技术成本过高的研究来说,它是肠道病原体定量的可行替代方法。